Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
73.3M
-
Shares change
-
+1.76M
-
Total reported value, excl. options
-
$1.43B
-
Value change
-
+$28.2M
-
Put/Call ratio
-
1.1
-
Number of buys
-
52
-
Number of sells
-
-52
-
Price
-
$19.44
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2020
135 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q1 2020.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.3M shares
of 226M outstanding shares and own 32.41% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (21.2M shares), Capital Research Global Investors (8.97M shares), BlackRock Inc. (4.9M shares), Capital International Investors (4.58M shares), VANGUARD GROUP INC (4.1M shares), FMR LLC (3.57M shares), Capital World Investors (2.98M shares), REGENTS OF THE UNIVERSITY OF CALIFORNIA (2.35M shares), VV Manager LLC (2.29M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.2M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.